You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 11,273,158

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,273,158 protect, and when does it expire?

Patent 11,273,158 protects ARISTADA and ARISTADA INITIO KIT and is included in two NDAs.

This patent has eight patent family members in six countries.

Summary for Patent: 11,273,158

Patent landscape, scope, and claims:

Title:	Aripiprazole dosing strategy
Abstract:	The present invention relates to methods of treating schizophrenia using a combination of aripiprazole, aripiprazole lauroxil, and a nanoparticle dispersion of aripiprazole lauroxil.
Inventor(s):	von Moltke; Lisa L. (Newton, MA), Weiden; Peter J. (Newton, MA), Hard; Marjie L. (Lexington, MA)
Assignee:	Alkermes Pharma Ireland Limited (Dublin, IE)
Application Number:	16/291,768
Patent Claim Types: see list of patent claims	Use;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 11,273,158

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-001	Oct 5, 2015		RX	Yes	No	11,273,158	⤷ Subscribe				TREATMENT OF SCHIZOPHRENIA	⤷ Subscribe
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-002	Oct 5, 2015		RX	Yes	No	11,273,158	⤷ Subscribe				TREATMENT OF SCHIZOPHRENIA	⤷ Subscribe
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes	11,273,158	⤷ Subscribe				TREATMENT OF SCHIZOPHRENIA	⤷ Subscribe
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-004	Jun 5, 2017		RX	Yes	No	11,273,158	⤷ Subscribe				TREATMENT OF SCHIZOPHRENIA	⤷ Subscribe
Alkermes Inc	ARISTADA INITIO KIT	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	209830-001	Jun 29, 2018		RX	Yes	No	11,273,158	⤷ Subscribe				TREATMENT OF SCHIZOPHRENIA	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,273,158

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019230014	⤷ Subscribe
Canada	3092335	⤷ Subscribe
China	112423754	⤷ Subscribe
European Patent Office	3761983	⤷ Subscribe
Japan	2021516241	⤷ Subscribe
Japan	2024014928	⤷ Subscribe
Japan	7384812	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.